Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 12;39(6):2701–2716. doi: 10.1007/s12325-022-02119-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 2 — Mean change in BCVA from baseline to Week 100^a. Full analysis set; last observation carried forward. The apparent spike at Week 52 and Week 100 is because this was a mandatory visit for all patients. ^aPatients had previously received 1 year of IVT-AFL treatment prior to the VIOLET study baseline. ^bAt Week 52 (primary endpoint), compared with IVT-AFL fixed, IVT-AFL T&E, and IVT-AFL PRN groups achieved a non-inferior outcome in mean BCVA change for the prespecified margin of 4 letters (p < 0.0001 for both comparisons). BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, IVT-AFL intravitreal aflibercept, PRN pro re nata; SD standard deviation, T&E treat-and-extend